GHCM
NKTR icon

Glen Harbor Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Glen Harbor Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$568K Buy
2,078
+293
+16% +$107K 0.01% 658
2019
Q2 		$953K Sell
1,785
-610
-25% -$306K 0.02% 497
2019
Q1 		$1.21M Sell
2,395
-5,697
-70% -$3.38M 0.03% 425
2018
Q4 		$3.99M Buy
8,092
+1,542
+24% +$931K 0.1% 210
2018
Q3 		$5.99M Buy
6,550
+5,796
+769% +$4.95M 0.12% 167
2018
Q2 		$552K Buy
754
+513
+213% +$592K 0.01% 610
2018
Q1 		$384K Sell
241
-1,040
-81% -$1.34M 0.01% 733
2017
Q4 		$1.15M Buy
1,281
+219
+21% +$130K 0.03% 402
2017
Q3 		$382K Buy
1,062
+144
+16% +$45K 0.01% 677
2017
Q2 		$269K Buy
918
+395
+76% +$114K 0.01% 786
2017
Q1 		$184K Buy
523
+53
+11% +$11.9K ﹤0.01% 761
2016
Q4 		$87K Buy
+470
New +$95.6K ﹤0.01% 945

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glen Harbor Capital Management's NKTR Position: Q3 2019 in Review

Glen Harbor Capital Management increased its Nektar Therapeutics (NKTR) stake by 16% in Q3 2019, buying an estimated $107K and bringing the position to 2,078 shares worth $568K. The position accounts for 0.01% of the portfolio, ranked #658.

Glen Harbor Capital Management first reported a position in NKTR in Q4 2016 and has held it in 12 quarters since. The position peaked at $5.99M in Q3 2018. 288 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • Glen Harbor Capital Management held 2,078 shares of Nektar Therapeutics worth $568K as of Q3 2019.
  • Glen Harbor Capital Management bought 293 Nektar Therapeutics shares in Q3 2019, an estimated $107K.
  • Nektar Therapeutics made up 0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #658 holding.
  • Glen Harbor Capital Management first reported a position in Nektar Therapeutics in Q4 2016 and has held it in 12 quarters since.
  • Glen Harbor Capital Management's Nektar Therapeutics position peaked at $5.99M in Q3 2018.
  • 288 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.